The Benefits of Conducting ADME-Tox Assays Early On

Media Coverage
The Benefits of Conducting ADME-Tox Assays Early On

Biocompare

The further a drug is allowed to progress along the development pipeline, the more expensive its failure becomes. It thus behooves researchers to let it fail early—ideally before in vivo studies—if that is to be its ultimate fate. In vitro ADME-tox assays—many automated or high throughput—are increasingly performed during the early stages of discovery to assess how a drug will likely behave when introduced into humans, weeding out those with unfavorable characteristics while allowing promising leads to move forward.

Read the full article here